Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Quick Summary:

SAN DIEGO, Dec.10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc.(NASDAQ:CRDF) ("Cardiff Oncology" or the "Company"), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the pricing of an underwritten offering of 15,384,619 shares of its common stock at an offering price of $2.60 per share, before deducting underwriting discounts and commissions.

The Company intends to use the net proceeds from this offering to fund clinical costs for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) and for working capital and other general corporate purposes.

The gross proceeds to the Company, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $40 million.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Globe Newswire

Category: InvestingBusiness

Markets: United States

Topics: IPOs Press Releases CRDF Financing News

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-12-10 @ 12:20:00 (4 days ago)

News Timezone: GMT +8:00

News Source URL: benzinga.com

Language: English

Article Length: 907 words

Reading Time: 6 minutes read

Sentences: 33 lines

Sentence Length: 28 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Benzinga

News ID: 24409043

View Article Analysis

About Benzinga

Main Topics: InvestingBusiness

Official Website: benzinga.com

Year Established: 2010

Headquarters: United States

News Last Updated: 1 days ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #54

Publisher Details

Frequently Asked Questions